pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

Hospital AI oversight lagging; senior leaders must take daily responsibility

Jul 22, 2026·read at STAT ↗Neutral

AI tools are now common in U.S. hospitals, handling tasks such as drafting clinical notes, flagging sepsis, screening imaging, processing prior authorizations, and responding to patient messages.

While the benefits are evident, most health systems still monitor these tools with the same slow, checklist-driven process used for older equipment like MRI scanners, often requiring quarterly meetings and six-month approvals.

The authors argue that this model is unsafe for AI and that fixing problems should not be left to IT departments alone; senior leadership must assume direct responsibility for AI oversight.

They call for daily AI governance to become a routine part of executive duties, ensuring that safety and performance are continuously monitored rather than reviewed only intermittently.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT+: Hospitals’ AI may be drifting. Who’s watching?”

read at STAT ↗
432 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
Bio TTestimVogelxotestosterone
topics
Approval

related stories

  • Sep 22Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDASTAT
  • Jul 22Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changerSTAT
  • Sep 18Opinion: More young men are coming to me for plastic surgery. The way I think about them has changedSTAT
  • Sep 18This Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and moreraps
  • Sep 4Disabled workers at greater risk of losing health insuranceSTAT